The glucagon-like peptides.

I. Introduction II. History of the Incretin Concept: Discovery of Gastric Inhibitory Polypeptide III. Discovery of GLP-1 IV. Structures of GLPs and Family of Glucagon-Related Peptides V. Tissue Distribution of the Expression of GLPs A. Pancreatic α-cells B. Intestinal L cells C. Central nervous system VI. Proglucagon Biosynthesis A. Organization/structure of the proglucagon gene B. Regulation of glucagon gene expression C. Posttranslational processing of proglucagon VII. Regulation of GLP Secretion A. Overview B. Intracellular signals C. Carbohydrates D. Fats E. Proteins F. Endocrine G. Neural H. GLP-2 VIII. Metabolism of GLPs A. GLP-1 B. GLP-2 IX. Physiological Actions of GLPs A. Overview B. Pancreatic islets C. Counterregulatory actions of GLP-1 and leptin on β-cells D. Stomach E. Lung F. Brain G. Liver, skeletal muscle, and fat H. Pituitary, hypothalamus, and thyroid I. Cardiovascular system J. GLP-2 X. GLP Receptors A. Structure B. Signaling C. Distribution D. Regulation E. GLP-2 XI. Pathophysiology o...

[1]  J. Brown,et al.  Stimulation of insulin secretion by gastric inhibitory polypeptide in man. , 1973, The Journal of clinical endocrinology and metabolism.

[2]  Shaoping Deng,et al.  Cloning and Functional Expression of the Human Islet GLP-1 Receptor: Demonstration That Exendin-4 Is an Agonist and Exendin-(9–39) an Antagonist of the Receptor , 1993, Diabetes.

[3]  J. Habener,et al.  Glucagon Gene Transcription Activation Mediated by Synergistic Interactions of pax-6 and cdx-2 with the p300 Co-activator* , 1999, The Journal of Biological Chemistry.

[4]  A. Joyner,et al.  Glucose intolerance but normal satiety in mice with a null mutation in the glucagon–like peptide 1 receptor gene , 1996, Nature Medicine.

[5]  S. Bloom,et al.  Characterization of glucagon-like peptide-1-(7–36)amide in the hypothalamus , 1989, Brain Research.

[6]  J. Habener,et al.  Transcription of the rat glucagon gene by the cyclic AMP response element-binding protein CREB is modulated by adjacent CREB-associated proteins , 1993, Molecular and cellular biology.

[7]  C. Strader,et al.  The amino terminal domain of the glucagon-like peptide-1 receptor is a critical determinant of subtype specificity. , 1996, Receptors & channels.

[8]  P. Zabel,et al.  Glucagon-Like Peptide I Reduces Postprandial Glycemic Excursions in IDDM , 1995, Diabetes.

[9]  J. Holst,et al.  Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[10]  P. Brubaker,et al.  Stereospecific effects of fatty acids on proglucagon-derived peptide secretion in fetal rat intestinal cultures. , 1995, Endocrinology.

[11]  N. Read,et al.  Effect of infusion of nutrient solutions into the ileum on gastrointestinal transit and plasma levels of neurotensin and enteroglucagon , 1984 .

[12]  D. Drucker,et al.  Intestinal growth-promoting properties of glucagon-like peptide-2 in mice. , 1997, The American journal of physiology.

[13]  N. Bunnett,et al.  Immunocytochemical localization of gastric inhibitory peptide and glucagon in the alimentary tract of ruminants. , 1986, Quarterly journal of experimental physiology.

[14]  R. Eaton,et al.  Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. , 1986, The Journal of clinical endocrinology and metabolism.

[15]  P. Blackmore,et al.  Absence of insulinotropic glucagon‐like peptide‐I(7–37) receptors on isolated rat liver hepatocytes , 1991, FEBS letters.

[16]  B. Ahrén.  Glucagon‐like peptide‐1 (GLP‐1): A gut hormone of potential interest in the treatment of diabetes , 1998, BioEssays : news and reviews in molecular, cellular and developmental biology.

[17]  J. Brown,et al.  Preparation of highly active enterogastrone. , 1969, Canadian journal of physiology and pharmacology.

[18]  P. F. Nielsen,et al.  Primary structures of glucagon and glucagon-like peptide isolated from the intestine of the parasitic phase lamprey Petromyzon marinus. , 1993, General and comparative endocrinology.

[19]  J. Brown,et al.  The insulinotropic action of gastric inhibitory polypeptide in the perfused isolated rat pancreas. , 1976, Endocrinology.

[20]  P. Brubaker.  Regulation of intestinal proglucagon-derived peptide secretion by intestinal regulatory peptides. , 1991, Endocrinology.

[21]  M. German,et al.  Genetic analysis reveals that PAX6 is required for normal transcription of pancreatic hormone genes and islet development. , 1997, Genes & development.

[22]  Moody Aj.  Gut glucagon-like immunoreactants. , 1980 .

[23]  M. Vranic,et al.  Fetal rat intestinal cells in monolayer culture: a new in vitro system to study the glucagon-like immunoreactive peptides. , 1987, Endocrinology.

[24]  J. Holst,et al.  Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects , 1995, Diabetes.

[25]  M. Hiratsuka,et al.  Alterations of plasma immunoreactive glucagon-like peptide-1 behavior in non-insulin-dependent diabetics. , 1990, Diabetes research and clinical practice.

[26]  J. Holst,et al.  Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. , 1995, The Journal of clinical endocrinology and metabolism.

[27]  M. Namba,et al.  Inhibition of pancreatic exocrine secretion and augmentation of the release of gut glucagon-like immunoreactive materials by intraileal administration of bile in the dog , 1983, Regulatory Peptides.

[28]  M. Permutt,et al.  Cloning and functional expression of the human glucagon-like peptide-1 (GLP-1) receptor. , 1993, Endocrinology.

[29]  Y. Matsuzawa,et al.  Glucagon-like peptide-1(7-36)amide enhances insulin-stimulated glucose uptake and decreases intracellular cAMP content in isolated rat adipocytes. , 1996, Biochimica et biophysica acta.

[30]  P. Gruss,et al.  The Pax4 gene is essential for differentiation of insulin-producing β cells in the mammalian pancreas , 1997, Nature.

[31]  J. L. Barre,et al.  STUDIES ON THE PHYSIOLOGY OF SECRETIN , 1930 .

[32]  J. Raufman,et al.  Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. , 1992, The Journal of biological chemistry.

[33]  D. Drucker,et al.  Effects of Aging and a High Fat Diet on Body Weight and Glucose Tolerance in Glucagon-Like Peptide-1 Receptor-/- Mice. , 1998, Endocrinology.

[34]  J. Polak,et al.  Immunofluorescent localization of enteroglucagon cells in the gastrointestinal tract of the dog , 1971, Gut.

[35]  J. Habener,et al.  Insulinotropic Glucagon-like Peptide-1-mediated Activation of Non-selective Cation Currents in Insulinoma Cells Is Mimicked by Maitotoxin* , 1997, The Journal of Biological Chemistry.

[36]  W. Taylor,et al.  Intestinal control of human postprandial gastric function: the role of components of jejunoileal chyme in regulating gastric secretion and gastric emptying. , 1981, Gastroenterology.

[37]  J. Habener,et al.  POU domain transcription factor brain 4 confers pancreatic alpha-cell-specific expression of the proglucagon gene through interaction with a novel proximal promoter G1 element , 1997, Molecular and cellular biology.

[38]  J. Kimmel,et al.  Chicken glucagon. Isolation and amino acid sequence studies. , 1975, The Journal of biological chemistry.

[39]  J. Gerich.  Oral hypoglycemic agents. , 1989, The New England journal of medicine.

[40]  E. Dumonteil,et al.  Differential Regulation of the Glucagon and Insulin I Gene Promoters by the Basic Helix-Loop-Helix Transcription Factors E47 and BETA2* , 1998, The Journal of Biological Chemistry.

[41]  M. Nauck.  Is glucagon-like peptide 1 an incretin hormone? , 1999, Diabetologia.

[42]  D. D’Alessio,et al.  Enteral Enhancement of Glucose Disposition by Both Insulin-Dependent and Insulin-Independent Processes: A Physiological Role of Glucagon-Like Peptide I , 1995, Diabetes.

[43]  P. Layer,et al.  Human pancreatic secretion and intestinal motility: effects of ileal nutrient perfusion. , 1990, The American journal of physiology.

[44]  J. Habener,et al.  Activation of a cAMP-regulated Ca-Signaling Pathway in Pancreatic -Cells by the Insulinotropic Hormone Glucagon-like Peptide-1 (*) , 1995, The Journal of Biological Chemistry.

[45]  M. Bernard.  DEFECT OF ORGANIZATION IN THE EXTERNAL EAR. , 1824 .

[46]  W. Creutzfeldt,et al.  Glucagon-like peptide-1(7-36)amide: characterization of the domain responsible for binding to its receptor on rat insulinoma RINm5F cells. , 1990, Journal of molecular endocrinology.

[47]  B. Göke,et al.  Glucagon‐like peptide‐1(7–36) amide is a new incretin/enterogastrone candidate , 1991, European journal of clinical investigation.

[48]  J. Markussen,et al.  Turkey glucagon: crystallization, amino acid composition and immunology. , 2009, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[49]  F. Levenez,et al.  Peptones stimulate both the secretion of the incretin hormone glucagon-like peptide 1 and the transcription of the proglucagon gene. , 1998, Diabetes.

[50]  D. Drucker.  Glucagon-Like Peptides , 1998, Diabetes.

[51]  L. Thim,et al.  Primary structure of glucagon from an elasmobranchian fish. Torpedo marmorata. , 1985, General and comparative endocrinology.

[52]  J. Habener,et al.  cAMP-dependent mobilization of intracellular Ca2+ stores by activation of ryanodine receptors in pancreatic beta-cells. A Ca2+ signaling system stimulated by the insulinotropic hormone glucagon-like peptide-1-(7-37). , 1999, The Journal of biological chemistry.

[53]  M. Freeman,et al.  A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. , 1991, Science.

[54]  B. Göke,et al.  GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery. , 1993, The American journal of physiology.

[55]  J. Rouse,et al.  Isolation and structures of coho salmon (Oncorhynchus kisutch) glucagon and glucagon-like peptide , 1986, Regulatory Peptides.

[56]  P. J. Larsen,et al.  Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. , 1996, The American journal of physiology.

[57]  D. Drucker,et al.  Induction of intestinal epithelial proliferation by glucagon-like peptide 2. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[58]  J. Holst,et al.  Overnight GLP-1 normalizes fasting but not daytime plasma glucose levels in NIDDM patients. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[59]  R. Unger,et al.  Characterization of the responses of circulating glucagon-like immunoreactivity to intraduodenal and intravenous administration of glucose. , 1968, The Journal of clinical investigation.

[60]  M. Rossor.  Neurotransmitters and CNS disease. Dementia. , 1982, Lancet.

[61]  J. Habener,et al.  A newly discovered role of transcription factors involved in pancreas development and the pathogenesis of diabetes mellitus. , 1998, Proceedings of the Association of American Physicians.

[62]  R. Yalow,et al.  Opossum insulin, glucagon and pancreatic polypeptide: Amino acid sequences , 1989, Peptides.

[63]  M. Permutt,et al.  Human Glucagon-Like Peptide-1 Receptor Gene in NIDDM: Identification and Use of Simple Sequence Repeat Polymorphisms in Genetic Analysis , 1994, Diabetes.

[64]  N. Seidah,et al.  Role of prohormone convertases in the tissue-specific processing of proglucagon. , 1996, Molecular endocrinology.

[65]  J. Slack.  Developmental biology of the pancreas. , 1995, Development.

[66]  I. Cleator,et al.  Release of immunoreactive gastric inhibitory polypeptide (IR-GIP) by oral ingestion of food substances. , 1975, American journal of surgery.

[67]  B. Göke,et al.  Ligand-induced regulation of glucagon-like peptide-I receptor function and expression in insulin-secreting beta cells. , 1996, Pancreas.

[68]  J. Habener,et al.  Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. , 1992, Endocrinology.

[69]  J. Thomsen,et al.  The amino acid sequence of human glucagon , 1972, FEBS letters.

[70]  J. Lauder,et al.  Distribution of glucagonlike peptide I (GLP‐I), glucagon, and glicentin in the rat brain: An immunocytochemical study , 1988, The Journal of comparative neurology.

[71]  J. Rouse,et al.  Isolation and characterization of reptilian insulin, glucagon, and pancreatic polypeptide: complete amino acid sequence of alligator (Alligator mississippiensis) insulin and pancreatic polypeptide. , 1984, General and comparative endocrinology.

[72]  J. Holst,et al.  Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity , 1998, Diabetologia.

[73]  C. Widmann,et al.  Heterologous Desensitization of the Glucagon-like Peptide-1 Receptor by Phorbol Esters Requires Phosphorylation of the Cytoplasmic Tail at Four Different Sites* , 1996, The Journal of Biological Chemistry.

[74]  D. Drucker,et al.  Activation of proglucagon gene transcription through a novel promoter element by the caudal-related homeodomain protein cdx-2/3 , 1996, Molecular and cellular biology.

[75]  M. Prentki,et al.  Glucose and glucoincretin peptides synergize to induce c‐fos, c‐jun, junB, zif‐268, and nur‐77 gene expression in pancreatic β(INS‐1) cells , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[76]  C. Ricordi,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1999 by The Endocrine Society Leptin Suppression of Insulin Secretion and Gene Expression in Human Pancreatic Islets: Implications for the Development of Adipogenic Diabetes Me , 2022 .

[77]  J. Cuber,et al.  Luminal glucagon-like peptide-1(7-36) amide-releasing factors in the isolated vascularly perfused rat colon. , 1995, The Journal of endocrinology.

[78]  J. Holst,et al.  Potential Therapeutic Levels of Glucagon-Like Peptide I Achieved in Humans by a Buccal Tablet , 1996, Diabetes Care.

[79]  E. Blázquez,et al.  Colocalization of Glucagon‐Like Peptide‐1 (GLP‐1) Receptors, Glucose Transporter GLUT‐2, and Glucokinase mRNAs in Rat Hypothalamic Cells: Evidence for a Role of GLP‐1 Receptor Agonists as an Inhibitory Signal for Food and Water Intake , 1996, Journal of neurochemistry.

[80]  P. Wellman,et al.  PVN infusion of GLP-1-(7-36) amide suppresses feeding but does not induce aversion or alter locomotion in rats. , 1998, The American journal of physiology.

[81]  S. Woods,et al.  Intraventricular GLP-1 reduces short- but not long-term food intake or body weight in lean and obese rats , 1998, Brain Research.

[82]  D. Drucker,et al.  Glucagon gene expression in vertebrate brain. , 1988, The Journal of biological chemistry.

[83]  J. Holst,et al.  Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans , 1994, Diabetes.

[84]  S. Bloom,et al.  A role for central glucagon‐like peptide‐1 in temperature regulation , 1996, Neuroreport.

[85]  T. Mommsen,et al.  Structure and biological activity of glucagon and glucagon-like peptide from a primitive bony fish, the bowfin (Amia calva). , 1993, The Biochemical journal.

[86]  B. Yusta,et al.  Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. , 1999, American journal of physiology. Gastrointestinal and liver physiology.

[87]  P. Foà,et al.  Elevated gut glucagon-like immunoreactive material in human and experimental diabetes and its suppression by somatostatin. , 1976, Metabolism: clinical and experimental.

[88]  J. Levy,et al.  Normalization of Insulin Responses to Glucose by Overnight Infusion of Glucagon-Like Peptide 1 (7–36) Amide in Patients With NIDDM , 1996, Diabetes.

[89]  C. Tack,et al.  The newly developed sulfonylurea glimepiride: a new ingredient, an old recipe. , 1998, The Netherlands journal of medicine.

[90]  P. Meda,et al.  The caudal-related Homeodomain Protein Cdx-2/3 Regulates Glucagon Gene Expression in Islet Cells* , 1996, The Journal of Biological Chemistry.

[91]  L. Thim,et al.  Primary structure of insulin and glucagon from the flounder (Platichthys flesus). , 1987, General and comparative endocrinology.

[92]  S. Ohashi,et al.  Structure-activity relationships of glucagon-like peptide-1(7-36)amide: insulinotropic activities in perfused rat pancreases, and receptor binding and cyclic AMP production in RINm5F cells. , 1994, The Journal of endocrinology.

[93]  P. Brubaker.  Control of glucagon-like immunoreactive peptide secretion from fetal rat intestinal cultures. , 1988, Endocrinology.

[94]  S. Ohashi,et al.  The structure-function relationship of GLP-1 related peptides in the endocrine function of the canine pancreas. , 1991, The Tohoku journal of experimental medicine.

[95]  P. Andrews,et al.  Multiple molecular forms of insulin and glucagon-like peptide from the Pacific ratfish (Hydrolagus colliei). , 1989, General and comparative endocrinology.

[96]  J. Holst,et al.  Reduced gastric inhibitory polypeptide but normal glucagon-like peptide 1 response to oral glucose in postmenopausal women with impaired glucose tolerance. , 1997, European journal of endocrinology.

[97]  H. Kuroki,et al.  Highly increased insulin secretion in a patient with postprandial hypoglycemia: role of glucagon-like peptide-1 (7-36) amide. , 1995, Endocrine journal.

[98]  J. Holst,et al.  Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. , 1996, The Journal of clinical endocrinology and metabolism.

[99]  R. Unger,et al.  The effects of triglyceride absorption upon glucagon, insulin, and gut glucagon-like immunoreactivity. , 1973, The Journal of clinical investigation.

[100]  D. Nathan,et al.  Insulinotropic Action of Glucagonlike Peptide-I-(7–37) in Diabetic and Nondiabetic Subjects , 1992, Diabetes Care.

[101]  J. Holst,et al.  Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. , 1992, The New England journal of medicine.

[102]  J. Chayvialle,et al.  Galanin inhibits glucagon-like peptide-1 secretion through pertussis toxin-sensitive G protein and ATP-dependent potassium channels in rat ileal L-cells. , 1998, The Journal of endocrinology.

[103]  S. Bonner-Weir,et al.  Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. , 1999, Diabetes.

[104]  B. Göke,et al.  Regulation of glucagon-like peptide-1 secretion from rat ileum by neurotransmitters and peptides. , 1995, The Journal of endocrinology.

[105]  D. Drucker,et al.  Glucagon gene transcription in an islet cell line is regulated via a protein kinase C-activated pathway. , 1987, The Journal of biological chemistry.

[106]  H. Lodish,et al.  Expression cloning of an adenylate cyclase-coupled calcitonin receptor. , 1991, Science.

[107]  J. Flier,et al.  Clinical review 94: What's in a name? In search of leptin's physiologic role. , 1998, The Journal of clinical endocrinology and metabolism.

[108]  D. Drucker,et al.  Mouse pancreatic beta-cells exhibit preserved glucose competence after disruption of the glucagon-like peptide-1 receptor gene. , 1998, Diabetes.

[109]  D. D’Alessio,et al.  Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons. , 1996, The Journal of clinical investigation.

[110]  J. Holst,et al.  Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. , 1997, American journal of physiology. Endocrinology and metabolism.

[111]  D. Drucker,et al.  Identification of glucagon-like peptide 1 (GLP-1) actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor signaling. , 1998, Diabetes.

[112]  J. Conlon,et al.  Characterization of the receptor for glucagon-like peptide-1(7-36)amide on plasma membranes from rat insulinoma-derived cells by covalent cross-linking. , 1989, Journal of molecular endocrinology.

[113]  J. Habener,et al.  Insulinotropic glucagonlike peptide-I(7–37)/(7–36)amide A new incretin hormone , 1992, Trends in Endocrinology & Metabolism.

[114]  N. Seidah,et al.  Proprotein Convertases , 2011, Methods in Molecular Biology.

[115]  C. Widmann,et al.  Desensitization and phosphorylation of the glucagon-like peptide-1 (GLP-1) receptor by GLP-1 and 4-phorbol 12-myristate 13-acetate. , 1996, Molecular endocrinology.

[116]  D. Pipeleers,et al.  Dual Glucagon Recognition by Pancreatic β-Cells via Glucagon and Glucagon-Like Peptide 1 Receptors , 1998, Diabetes.

[117]  M. Byrne,et al.  Glucagon-Like Peptide 1 Improves the Ability of the β-Cell to Sense and Respond to Glucose in Subjects With Impaired Glucose Tolerance , 1998, Diabetes.

[118]  F J Grant,et al.  Expression cloning and signaling properties of the rat glucagon receptor. , 1993, Science.

[119]  W. Creutzfeldt,et al.  Release of gastric inhibitory polypeptide (GIP) by intraduodenal acidification in rats and humans and abolishment of the incretin effect of acid by GIP-antiserum in rats. , 1979, Gastroenterology.

[120]  Graeme I. Bell,et al.  Exon duplication and divergence in the human preproglucagon gene , 1983, Nature.

[121]  J. Philippe,et al.  Homologous DNA sequences and cellular factors are implicated in the control of glucagon and insulin gene expression , 1995, Molecular and cellular biology.

[122]  T. Adrian,et al.  Deoxycholate is an important releaser of peptide YY and enteroglucagon from the human colon. , 1993, Gut.

[123]  P. J. Larsen,et al.  Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem , 1997, Neuroscience.

[124]  I. Valverde,et al.  Inositolphosphoglycans and diacylglycerol are possible mediators in the glycogenic effect of GLP‐1(7‐36)amide in BC3H‐1 myocytes , 1996, Cell biochemistry and function.

[125]  P. de Neef,et al.  Pituitary adenylate cyclase-activating polypeptide receptors of types I and II and glucagon-like peptide-I receptors are expressed in the rat medullary carcinoma of the thyroid cell line 6/23. , 1994, Endocrinology.

[126]  K. Houseknecht,et al.  The biology of leptin: a review. , 1998, Journal of animal science.

[127]  J. Markussen,et al.  Rabbit Glucagon: Isolation, Crystallization and Amino Acid Composition , 1972, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[128]  C. Cheeseman.  Upregulation of SGLT-1 transport activity in rat jejunum induced by GLP-2 infusion in vivo. , 1997, American journal of physiology. Regulatory, integrative and comparative physiology.

[129]  D. Drucker,et al.  Printed in U.S.A. Copyright © 1997 by The Endocrine Society Circulating and Tissue Forms of the Intestinal Growth Factor, Glucagon-Like Peptide-2* , 2022 .

[130]  K. Yamatani,et al.  GLP-1 secretion coupled with Na/glucose transporter from the isolated perfused canine ileum , 1993 .

[131]  N. Hoosein,et al.  Human glucagon‐like peptides 1 and 2 activate rat brain adenylate cyclase , 1984, FEBS letters.

[132]  B. Göke,et al.  Regulation of glucagon-like peptide release from the isolated perfused rat ileum by nutrients, peptides and neuromediators , 1993 .

[133]  J. Egan,et al.  Glucagon-like peptide-1(7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action. , 1994, Endocrinology.

[134]  R. Heller,et al.  Intra-islet regulation of hormone secretion by glucagon-like peptide-1-(7--36) amide. , 1995, The American journal of physiology.

[135]  H. Bernstein,et al.  The glucagon/glucagon-like immunoreactivities in neurons of the human brain. , 2009, Experimental and clinical endocrinology.

[136]  P. Foà,et al.  Glucose, Insulin, Pancreatic Glucagon and Glucagon-like Immunoreactive Materials in the Plasma of Normal and Diabetic Children. Effect of the Initial Insulin Treatment* , 1975, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[137]  E. Nishimura,et al.  Regulation of glucagon and glucagon-like peptide-1 receptor messenger ribonucleic acid expression in cultured rat pancreatic islets by glucose, cyclic adenosine 3',5'-monophosphate, and glucocorticoids. , 1995, Endocrinology.

[138]  A. Wilks,et al.  Identical mRNA for preproglucagon in pancreas and gut. , 1987, European journal of biochemistry.

[139]  C. Strader,et al.  Cloning and functional expression of a human glucagon-like peptide-1 receptor. , 1993, Biochemical and biophysical research communications.

[140]  J. Philippe,et al.  The Upstream Promoter Element of the Glucagon Gene, G1, Confers Pancreatic Alpha Cell-specific Expression (*) , 1995, The Journal of Biological Chemistry.

[141]  P. Gruss,et al.  Pax6 is required for differentiation of glucagon-producing α-cells in mouse pancreas , 1997, Nature.

[142]  D. Drucker,et al.  Proglucagon gene expression is regulated by a cyclic AMP-dependent pathway in rat intestine. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[143]  A. Moody,et al.  Ontogeny of immunoreactive glicentin in the human gastrointestinal tract and endocrine pancreas , 1982, Regulatory Peptides.

[144]  R. Dinerstein,et al.  Identification and localization of glucagon-related peptides in rat brain. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[145]  Yihong Wang,et al.  Novel signal transduction and peptide specificity of glucagon‐like peptide receptor in 3T3‐L1 adipocytes , 1997, Journal of cellular physiology.

[146]  J. Egan,et al.  GIP regulates glucose transporters, hexokinases, and glucose-induced insulin secretion in RIN 1046-38 cells , 1996, Molecular and Cellular Endocrinology.

[147]  D. Kipnis,et al.  Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic sujbjects. , 1967, The Journal of clinical investigation.

[148]  H. Koop,et al.  Effect of glucagon-like peptide-1 on gastric somatostatin and gastrin secretion in the rat. , 1990, Scandinavian journal of gastroenterology.

[149]  R. Bellens,et al.  INSULIN RESPONSE AND GLUCOSE-C14 DISAPPEARANCE RATE DURING THE GLUCOSE TOLERANCE TEST IN THE UNANESTHETIZED DOG. , 1963, Metabolism: clinical and experimental.

[150]  M. Stoffel,et al.  Human Glucagon-Like Peptide-1 Receptor Gene: Localization to Chromosome Band 6p21 by Fluorescence In Situ Hybridization and Linkage of a Highly Polymorphic Simple Tandem Repeat DNA Polymorphism to Other Markers on Chromosome 6 , 1993, Diabetes.

[151]  J. Habener,et al.  Functional receptors for the insulinotropic hormone glucagon‐like peptide‐I(7–37) on a somatostatin secreting cell line , 1991, FEBS letters.

[152]  P. Brubaker,et al.  Proglucagon processing in islet and intestinal cell lines , 1996, Regulatory Peptides.

[153]  L. Thim,et al.  Primary structures of three fragments of proglucagon from the pancreatic islets of the daddy Sculpin (Cottus scorpius). , 1987, European journal of biochemistry.

[154]  D. Romsos,et al.  Leptin constrains acetylcholine-induced insulin secretion from pancreatic islets of ob/ob mice. , 1997, The Journal of clinical investigation.

[155]  B. Göke,et al.  Cloning and Characterization of the 5′ Flanking Sequences (Promoter Region) of the Human GLP-1 Receptor Gene , 1997, Peptides.

[156]  P. Froguel,et al.  Cloning, Functional Expression, and Chromosomal Localization of the Human Pancreatic Islet Glucose-Dependent Insulinotropic Polypeptide Receptor , 1995, Diabetes.

[157]  B. Thorens.  Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[158]  J. Holst,et al.  Glucagon-Like Peptide I Enhances the Insulinotropic Effect of Glibenclamide in NIDDM Patients and in the Perfused Rat Pancreas , 1996, Diabetes Care.

[159]  J. Holst,et al.  All products of proglucagon are elevated in plasma from uremic patients. , 1992, The Journal of clinical endocrinology and metabolism.

[160]  D. Steiner,et al.  Cloning of complementary DNAs encoding islet amyloid polypeptide, insulin, and glucagon precursors from a New World rodent, the degu, Octodon degus. , 1990, Molecular endocrinology.

[161]  Hattie Wh.  Mechanism of Pancreatic Secretion. , 1926 .

[162]  J. Holst,et al.  Rat parietal cell receptors for GLP-1-(7-36) amide: northern blot, cross-linking, and radioligand binding. , 1994, The American journal of physiology.

[163]  L. Orci,et al.  FUNCTIONAL SUBDIVISION OF ISLETS OF LANGERHANS AND POSSIBLE ROLE OF D CELLS , 1975, The Lancet.

[164]  R. W. Flanagan,et al.  Glucagonoma syndrome demonstrating giant duodenal villi. , 1984, Gut.

[165]  J. Conlon,et al.  Receptors for glucagon-like peptide-1(7-36) amide on rat insulinoma-derived cells. , 1988, The Journal of endocrinology.

[166]  M. Brownstein,et al.  Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. , 1993, Endocrinology.

[167]  A. Babenko,et al.  A view of sur/KIR6.X, KATP channels. , 1998, Annual review of physiology.

[168]  J. Habener,et al.  Homologous desensitization of the insulinotropic glucagon-like peptide-I (7-37) receptor on insulinoma (HIT-T15) cells. , 1991, Endocrinology.

[169]  I. Hramiak,et al.  Subcutaneous Glucagon-Like Peptide I Combined With Insulin Normalizes Postcibal Glycemic Excursions in IDDM , 1997, Diabetes Care.

[170]  J. Holst,et al.  Glucagon-like peptide-2 inhibits centrally induced antral motility in pigs. , 1998, Scandinavian journal of gastroenterology.

[171]  A. Ohneda,et al.  Response of plasma glicentin to fat ingestion in piglets. , 1987, Diabetes research and clinical practice.

[172]  R. Pederson,et al.  Improved Glucose Tolerance in Zucker Fatty Rats by Oral Administration of the Dipeptidyl Peptidase IV Inhibitor Isoleucine Thiazolidide , 1998, Diabetes.

[173]  V. Mutt,et al.  Amino acid sequence and heterogeneity of gastric inhibitory polypeptide (GIP) , 1981, FEBS letters.

[174]  J. Holst,et al.  Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1 , 1998, Pflügers Archiv.

[175]  J. Holst,et al.  Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. , 1988, Endocrinology.

[176]  F. Sundler,et al.  Endocrine cells in human intestine: an immunocytochemical study. , 1983, Gastroenterology.

[177]  V. Mutt,et al.  A qualitative comparison of canine plasma gastroenteropancreatic hormone responses to bombesin and the porcine gastrin-releasing peptide (GRP) , 1981, Regulatory Peptides.

[178]  I. Valverde,et al.  Inositolphosphoglycans are possible mediators of the glucagon-like peptide 1 (7–36)amide action in the liver , 1996, Journal of endocrinological investigation.

[179]  W. Chance,et al.  Prevention of parenteral nutrition-induced gut hypoplasia by coinfusion of glucagon-like peptide-2. , 1997, The American journal of physiology.

[180]  C. Potten,et al.  The distribution of endocrine cells along the mouse intestine: A quantitative immunocytochemical study , 1988, Virchows Archiv. B, Cell pathology including molecular pathology.

[181]  C. Beglinger,et al.  rapid communication Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2 , 2022 .

[182]  L. B. Knudsen,et al.  Structure-activity studies of glucagon-like peptide-1. , 1994, The Journal of biological chemistry.

[183]  M. Vranic,et al.  Chromatographic pattern of extrapancreatic glucagon and glucagon-like immunoreactivity before and during stimulation by epinephrine and participation of glucagon in epinephrine-induced hepatic glucose overproduction. , 1981, Surgery.

[184]  A. Young,et al.  Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). , 1999, Diabetes.

[185]  S. Rössner,et al.  Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. , 1999, International Journal of Obesity.

[186]  B. Göke,et al.  Blood Glucose Lowering and Glucagonostatic Effects of Glucagon-Like Peptide I in Insulin-Deprived Diabetic Dogs , 1997, Diabetes.

[187]  L. B. Knudsen,et al.  Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. , 1996, European journal of pharmacology.

[188]  E. Blázquez,et al.  Autoradiographic localization of receptors for glucagon-like peptide-1(7–36) amide in rat brain , 1992, Neuropeptides.

[189]  W. Bromer,et al.  Amino acid sequence of bovine glucagon. , 1971, The Journal of biological chemistry.

[190]  J. Holst,et al.  Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7–36 amide]) in patients with NIDDM , 1996, Diabetologia.

[191]  B. Wolffenbuttel,et al.  New treatments for patients with type 2 diabetes mellitus. , 1996, Postgraduate medical journal.

[192]  D. Drucker,et al.  Alterations in proglucagon processing and inhibition of proglucagon gene expression in transgenic mice which contain a chimeric proglucagon-SV40 T antigen gene. , 1992, The Journal of biological chemistry.

[193]  P. Brubaker,et al.  Proglucagon processing in an islet cell line: effects of PC1 overexpression and PC2 depletion. , 1998, Endocrinology.

[194]  R. Unger,et al.  Entero-insular axis. , 1969, Archives of internal medicine.

[195]  I. Valverde,et al.  Inositolphosphoglycans possibly mediate the effects of glucagon‐like peptide‐1(7‐36)amide on rat liver and adipose tissue , 1998, Cell biochemistry and function.

[196]  K. Shima,et al.  Release of glucagon-like peptide 1 immunoreactivity from the perfused rat pancreas. , 1987, Acta endocrinologica.

[197]  R. Goodman,et al.  Intestinal glucagon mRNA identified by hybridization to a cloned islet cDNA encoding a precursor. , 1981, Biochemical and biophysical research communications.

[198]  K. Shima,et al.  Identification and localization of glucagon-like peptide-1 and its receptor in rat brain. , 1987, Endocrinology.

[199]  D. Drucker,et al.  Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[200]  J. Polak,et al.  Cytochemical and ultrastructural differentiation of enteroglucagon and pancreatic-type glucagon cells of the gastrointestinal tract , 1976, Virchows Archiv. B, Cell pathology.

[201]  P. Blache,et al.  Diurnal profile of oxyntomodulin-like immunoreactivity in duodenal ulcer patients. , 1993, Scandinavian journal of gastroenterology.

[202]  E. Plisetskaya,et al.  Glucagon and glucagon-like peptides in fishes. , 1996, International review of cytology.

[203]  W. Knepel,et al.  Glucagon Gene G3 Enhancer: Evidence that Activity Depends on Combination of an Islet-Specific Factor and a Winged Helix Protein , 1997, Biological chemistry.

[204]  S. Bonner-Weir,et al.  Microcirculation of the Islets of Langerhans: Long Beach Veterans Administration Regional Medical Education Center Symposium , 1996, Diabetes.

[205]  M. Wheeler,et al.  The role of the free cytosolic calcium level in beta-cell signal transduction by gastric inhibitory polypeptide and glucagon-like peptide I(7-37). , 1993, Endocrinology.

[206]  C. Widmann,et al.  Internalization and homologous desensitization of the GLP-1 receptor depend on phosphorylation of the receptor carboxyl tail at the same three sites. , 1997, Molecular endocrinology.

[207]  J. Chayvialle,et al.  Regulation of glucagon-like peptide-1-(7-36) amide secretion by intestinal neurotransmitters and hormones in the isolated vascularly perfused rat colon. , 1994, Endocrinology.

[208]  D. Drucker,et al.  Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse. , 1994, Endocrinology.

[209]  K. Shima,et al.  Identification of Glucagon-Like Peptide-1(7–36) Amide in Rat Brain , 1989, Annals of clinical biochemistry.

[210]  B. Göke,et al.  Five Out of Six Tryptophan Residues in the N-Terminal Extracellular Domain of the Rat GLP-1 Receptor Are Essential for its Ability to Bind GLP-1 , 1997, Peptides.

[211]  D. Drucker,et al.  Leptin Sensitivity in Nonobese Glucagon-Like Peptide I Receptor −/− Mice , 1997, Diabetes.

[212]  J. Holst,et al.  Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. , 1991, The Journal of clinical investigation.

[213]  T. Adrian,et al.  Effects of an elemental diet, inert bulk and different types of dietary fibre on the response of the intestinal epithelium to refeeding in the rat and relationship to plasma gastrin, enteroglucagon, and PYY concentrations. , 1987, Gut.

[214]  T. Ogihara,et al.  Tissue-Specific and Glucose-Dependent Expression of Receptor Genes for Glucagon and Glucagon-Like Peptide-1 (GLP-1) , 1997, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[215]  V. Marks,et al.  Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. , 1993, The Journal of endocrinology.

[216]  S. Grinstein,et al.  Identification of Glucagon-like Peptide-2 (GLP-2)-activated Signaling Pathways in Baby Hamster Kidney Fibroblasts Expressing the Rat GLP-2 Receptor* , 1999, The Journal of Biological Chemistry.

[217]  R. Spiller,et al.  Further characterisation of the 'ileal brake' reflex in man--effect of ileal infusion of partial digests of fat, protein, and starch on jejunal motility and release of neurotensin, enteroglucagon, and peptide YY. , 1988, Gut.

[218]  H. Sasaki,et al.  Hyperglycaemia but not hyperinsulinaemia prevents the secretion of glucagon-like peptide-1 (7-36 amide) stimulated by fat ingestion , 1991 .

[219]  S. Ohashi,et al.  Comparison of the effects of glucagon-like peptide-1-(1-37) and -(7-37) and glucagon on islet hormone release from isolated perfused canine and rat pancreases. , 1989, Endocrinology.

[220]  J. Holst,et al.  Glucagon-Like Peptide I Receptors in the Subfornical Organ and the Area Postrema Are Accessible to Circulating Glucagon-Like Peptide I , 1996, Diabetes.

[221]  S. Ohashi,et al.  Reduced Insulinotropic Effects of Glucagonlike Peptide I-(7–36)-Amide and Gastric Inhibitory Polypeptide in Isolated Perfused Diabetic Rat Pancreas , 1990, Diabetes.

[222]  J. Brown,et al.  Further purification of a polypeptide demonstrating enterogastrone activity , 1970, The Journal of physiology.

[223]  S. Bloom,et al.  Molecular forms of glucagon‐like peptides in man , 1985, FEBS letters.

[224]  J. Schrezenmeir,et al.  Biological activity of GLP-1-analogues with N-terminal modifications , 1999, Regulatory Peptides.

[225]  J. Beck,et al.  Stimulation of Release of Insulin by an Extract of Intestinal Mucosa , 1966, Diabetes.

[226]  S. Berson,et al.  Immunoassay of Endogenous Plasma Insulin in Man , 1960 .

[227]  M. Namba,et al.  Glucagonostatic and Insulinotropic Action of Glucagonlike Peptide I-(7–36)-Amide , 1989, Diabetes.

[228]  J. Habener,et al.  Leptin Suppression of Insulin Secretion by the Activation of ATP-Sensitive K+ Channels in Pancreatic β-Cells , 1997, Diabetes.

[229]  G. Weir,et al.  Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. , 1987, The Journal of clinical investigation.

[230]  J. Brown,et al.  Functional expression of the rat pancreatic islet glucose-dependent insulinotropic polypeptide receptor: ligand binding and intracellular signaling properties. , 1995, Endocrinology.

[231]  L. Thim,et al.  Primary structures of peptides derived from proglucagon isolated from the pancreas of the elasmobranch fish, Scyliorhinus canicula , 1994, Peptides.

[232]  L. Thim,et al.  Primary structure of glucagon from the gut of the common dogfish (Scyliorhinus canicula) , 1987, FEBS letters.

[233]  H. Elrick,et al.  PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION. , 1964, The Journal of clinical endocrinology and metabolism.

[234]  J. Holst,et al.  Biological Effects and Metabolic Rates of Glucagonlike Peptide-1 7–36 Amide and Glucagonlike Peptide-1 7–37 in Healthy Subjects Are Indistinguishable , 1993, Diabetes.

[235]  J. Holst,et al.  Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. , 1993, The Journal of clinical investigation.

[236]  B. Göke,et al.  Contribution of a PS1‐like element to the tissue‐ and cell‐specific expression of the human GLP‐1 receptor gene , 1998, FEBS letters.

[237]  P. Vergara,et al.  Sympathetic pathways mediate GLP-1 actions in the gastrointestinal tract of the rat , 1998, Regulatory Peptides.

[238]  J. Holst,et al.  Secretion of glucagon-like peptide-1 and reactive hypoglycemia after partial gastrectomy. , 1994, Digestion.

[239]  J. Brown,et al.  Cellular localization of gastric inhibitory polypeptide in the duodenum and jejunum , 1973, Gut.

[240]  D. Drucker,et al.  Activation of proglucagon gene transcription by protein kinase-A in a novel mouse enteroendocrine cell line. , 1994, Molecular endocrinology.

[241]  P. Blache,et al.  Distribution of oxyntomodulin and glucagon in the gastrointestinal tract and the plasma of the rat. , 1987, Endocrinology.

[242]  H. Trusheim,et al.  Gene Expression of the Human Glucagon-Like Peptide-1 Receptor Is Regulated by Sp1 and Sp3. , 1999, Endocrinology.

[243]  R. Pederson,et al.  Localization of the domains involved in ligand binding and activation of the glucose-dependent insulinotropic polypeptide receptor. , 1997, Endocrinology.

[244]  D. Swallow,et al.  Regional expression of epithelial dipeptidyl peptidase IV in the human intestines. , 1994, Biochemical and biophysical research communications.

[245]  S. Bloom,et al.  GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN , 1987, The Lancet.

[246]  R. Unger,et al.  Localization of glucagon in the alpha cells in the pancreatic islet by immunofluorescent technics. , 1962, Diabetes.

[247]  J. Nielsen,et al.  Truncated glucagon‐like peptide‐1 (proglucagon 78–107 amide), an intestinal insulin‐releasing peptide, has specific receptors on rat insulinoma cells (RIN 5AH) , 1988, FEBS letters.

[248]  M. Wheeler,et al.  Ligand-specificity of the rat GLP-I receptor recombinantly expressed in Chinese hamster ovary (CHO-) cells. , 1994, Zeitschrift fur Gastroenterologie.

[249]  J. Dupré,et al.  Effects of Ingestion of Triglyceride or Galactose on Secretion of Gastric Inhibitory Polypeptide and on Responses to Intravenous Glucose in Normal and Diabetic Subjects , 1978, Diabetes.

[250]  V. Marks,et al.  Effect of the entero-pancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1(7-36) amide, on fatty acid synthesis in explants of rat adipose tissue. , 1991, The Journal of endocrinology.

[251]  J. Brown,et al.  Gastric Inhibitory Polypeptide: Its Physiologic Release and Insulinotropic Action in the Dog , 1975, Diabetes.

[252]  J. Habener,et al.  Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37) , 1993, Nature.

[253]  J. Hicks,et al.  Isolation and structural characterization of insulin, glucagon and somatostatin from the turtle, Pseudemys scripta , 1990, Peptides.

[254]  J. S. Gray,et al.  IS A DUODENAL HORMONE INVOLVED IN CARBOHYDRATE METABOLISM , 1940 .

[255]  P. Brubaker,et al.  Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop. , 1993, Endocrinology.

[256]  G. Wolf,et al.  Orexins: a newly discovered family of hypothalamic regulators of food intake. , 2009, Nutrition reviews.

[257]  D. Drucker,et al.  Cell-specific post-translational processing of preproglucagon expressed from a metallothionein-glucagon fusion gene. , 1986, The Journal of biological chemistry.

[258]  D. Hörsch,et al.  Galanin is a potent inhibitor of glucagon-like peptide-1 secretion from rat ileum , 1996, Peptides.

[259]  V. Han,et al.  Cellular localization of proglucagon/glucagon‐like peptide I messenger RNAs in rat brain , 1986, Journal of neuroscience research.

[260]  I. Valverde,et al.  Physiological Effect of Glucagon in Human Isolated Adipocytes , 1995, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[261]  J. Habener,et al.  A role for Ca2+-sensitive nonselective cation channels in regulating the membrane potential of pancreatic beta-cells. , 1998, Diabetes.

[262]  J. Polak,et al.  Measurement of gut hormonal peptides in biopsies from human stomach and proximal small intestine. , 1983, Gut.

[263]  S. Mojsov,et al.  Tissue‐specific expression of the human receptor for glucagon‐like peptide‐I: brain, heart and pancreatic forms have the same deduced amino acid sequences , 1995, FEBS letters.

[264]  D. Drucker,et al.  Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[265]  F. Ashcroft,et al.  Calcium-independent potentiation of insulin release by cyclic AMP in single β-cells , 1993, Nature.

[266]  D. Smith,et al.  Glucagon-like peptide-1 (GLP-1) releases thyrotropin (TSH): characterization of binding sites for GLP-1 on alpha-TSH cells. , 1996, Endocrinology.

[267]  M. Nakata,et al.  Glucagon-like peptide-1-(7-36)amide and a rise in cyclic adenosine 3',5'-monophosphate increase cytosolic free Ca2+ in rat pancreatic beta-cells by enhancing Ca2+ channel activity. , 1993, Endocrinology.

[268]  S. Bloom.  An enteroglucagon tumour , 1972, Gut.

[269]  F. Sundler,et al.  GLP‐1 and GLP‐17‐36 Amide: Influences on Basal and Stimulated Insulin and Glucagon Secretion in the Mouse , 1991, Pancreas.

[270]  D. B. Rountree,et al.  Nutrient-independent increases in proglucagon and ornithine decarboxylase messenger RNAs after jejunoileal resection. , 1992, Gastroenterology.

[271]  P. Halban,et al.  Role of the Prohormone Convertase PC3 in the Processing of Proglucagon to Glucagon-like Peptide 1* , 1997, The Journal of Biological Chemistry.

[272]  R. Pederson,et al.  Altered Glucose Dependence of Glucagon-Like Peptide I(7–36)–Induced Insulin Secretion from the Zucker (fa/fa) Rat Pancreas , 1995, Diabetes.

[273]  P. Lefèbvre.  Glucagon and its Family Revisited , 1995, Diabetes Care.

[274]  J. Holst,et al.  Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. , 1998, American journal of physiology. Gastrointestinal and liver physiology.

[275]  I. Merchenthaler,et al.  Glucagon-like peptide-1 receptor (GLP1-R) mRNA in the rat hypothalamus. , 1996, Endocrinology.

[276]  D. Drucker,et al.  Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. , 1997, The American journal of physiology.

[277]  M. Wheeler,et al.  Scanning of the glucagon-like peptide-1 receptor localizes G protein-activating determinants primarily to the N terminus of the third intracellular loop. , 1997, Molecular endocrinology.

[278]  G. Greenberg,et al.  Effect of total parenteral nutrition on gut hormone release in humans. , 1981, Gastroenterology.

[279]  J. Brown,et al.  Radioimmunoassay for gastric inhibitory polypeptide. , 1974, Gastroenterology.

[280]  Y. Yiangou,et al.  Development of neuroendocrine tumors in the gastrointestinal tract of transgenic mice. Heterogeneity of hormone expression. , 1990, The American journal of pathology.

[281]  D. Drucker,et al.  Intestinal response to growth factors administered alone or in combination with human [Gly2]glucagon-like peptide 2. , 1997, American journal of physiology. Gastrointestinal and liver physiology.

[282]  R. Pederson,et al.  Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. , 1995, Endocrinology.

[283]  D. Gorenstein,et al.  Structure of glucagon-like peptide (7-36) amide in a dodecylphosphocholine micelle as determined by 2D NMR. , 1994, Biochemistry.

[284]  W. Malaisse,et al.  Preserved GLP-I Effects on Glycogen Synthase a Activity and Glucose Metabolism in Isolated Hepatocytes and Skeletal Muscle From Diabetic Rats , 1997, Diabetes.

[285]  P. J. Larsen,et al.  Distribution of GLP‐1 Binding Sites in the Rat Brain: Evidence that Exendin‐4 is a Ligand of Brain GLP‐1 Binding Sites , 1995, The European journal of neuroscience.

[286]  B. Göke,et al.  Molecular cloning of a cDNA encoding for the GLP-1 receptor expressed in rat lung. , 2009, Experimental and clinical endocrinology.

[287]  B. Göke,et al.  Gastric emptying and release of incretin hormones after glucose ingestion in humans. , 1996, The Journal of clinical investigation.

[288]  P. Blache,et al.  Oxyntomodulin and glicentin: brain-gut peptides in the rat. , 1988, Endocrinology.

[289]  E. Oetjen,et al.  Membrane depolarization and calcium influx induce glucagon gene transcription in pancreatic islet cells through the cyclic AMP-responsive element. , 1993, The Journal of biological chemistry.

[290]  T. Schermerhorn,et al.  cAMP enhances insulin secretion by an action on the ATP-sensitive K+ channel-independent pathway of glucose signaling in rat pancreatic islets. , 1999, Diabetes.

[291]  P. Rorsman,et al.  Stimulation of cloned human glucagon‐like peptide 1 receptor expressed in HEK 293 cells induces cAMP‐dependent activation of calcium‐induced calcium release , 1995, FEBS letters.

[292]  J. Diamond,et al.  Luminal glucose concentrations in the gut under normal conditions. , 1990, The American journal of physiology.

[293]  M. Wheeler,et al.  Functional expression of the rat glucagon-like peptide-I receptor, evidence for coupling to both adenylyl cyclase and phospholipase-C. , 1993, Endocrinology.

[294]  B. Göke,et al.  Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. , 1993, The Journal of biological chemistry.

[295]  D. Steiner,et al.  Differential Processing of Proglucagon by the Subtilisin-like Prohormone Convertases PC2 and PC3 to Generate either Glucagon or Glucagon-like Peptide (*) , 1995, The Journal of Biological Chemistry.

[296]  John R. Christiansen,et al.  Glucagon-like peptide-1 7-36 amide and peptide YY from the L-cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man. , 1994, Scandinavian journal of gastroenterology.

[297]  R. Goodman,et al.  Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[298]  J. Brown,et al.  Release of gastric inhibitory polypeptide from cultured canine endocrine cells. , 1994, The American journal of physiology.

[299]  D. Barber,et al.  Somatostatin and muscarinic inhibition of canine enteric endocrine cells: cellular mechanisms. , 1987, The American journal of physiology.

[300]  J. Habener,et al.  The adipoinsular axis: effects of leptin on pancreatic β-cells , 2000 .

[301]  L. Orci.  The microanatomy of the islets of Langerhans. , 1976, Metabolism: clinical and experimental.

[302]  J. Holst,et al.  GLP-1 : a humoral mediator of the ileal brake in humans ? , 1993 .

[303]  R. Turner,et al.  Drugs on the Horizon for Treatment of Type 2 Diabetes , 1995, Diabetic medicine : a journal of the British Diabetic Association.

[304]  I. Valverde,et al.  Glucagon‐like peptide 1: A potent glycogenic hormone , 1994, FEBS letters.

[305]  S. Bloom,et al.  Leptin interacts with glucagon‐like peptide‐1 neurons to reduce food intake and body weight in rodents , 1997, FEBS letters.

[306]  N. Greig,et al.  Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats. , 1997, The Journal of clinical investigation.

[307]  T. Murakami,et al.  Extrapancreatic action of truncated glucagon-like peptide-I in Otsuka Long-Evans Tokushima Fatty rats, an animal model for non-insulin-dependent diabetes mellitus. , 1997, Metabolism: clinical and experimental.

[308]  A. Kumar,et al.  Mammalian pancreatic preproglucagon contains three glucagon-related peptides. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[309]  D. Steiner,et al.  Proglucagon is processed to glucagon by prohormone convertase PC2 in alpha TC1-6 cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[310]  D. Pipeleers,et al.  Expression and Functional Activity of Glucagon, Glucagon-Like Peptide I, and Glucose-Dependent Insulinotropic Peptide Receptors in Rat Pancreatic Islet Cells , 1996, Diabetes.

[311]  P. Flatt,et al.  NH2-terminally modified gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced antihyperglycemic activity. , 1999, Diabetes.

[312]  D. Smith,et al.  Glucagon-like peptide-1 is a physiological incretin in rat. , 1995, The Journal of clinical investigation.

[313]  J. Philippe.  Hepatocyte-nuclear factor 3 beta gene transcripts generate protein isoforms with different transactivation properties on the glucagon gene. , 1995, Molecular endocrinology.

[314]  A. S. French,et al.  FIVE pS ANION CHANNELS IN HUMAN AIRWAY EPITHELIAL CELLS , 1992 .

[315]  B. Berks,et al.  Isolation and structural characterization of insulin and glucagon from the holocephalan species Callorhynchus milii (elephantfish). , 1989, The Biochemical journal.

[316]  P. Brubaker,et al.  Gastrin-releasing peptide is a novel mediator of proximal nutrient-induced proglucagon-derived peptide secretion from the distal gut. , 1996, Endocrinology.

[317]  J. Egan,et al.  GLP-1 action in L6 myotubes is via a receptor different from the pancreatic GLP-1 receptor. , 1998, American journal of physiology. Cell physiology.

[318]  J. Holst,et al.  Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gut , 1987, FEBS letters.

[319]  I. Lindberg,et al.  Processing of Mouse Proglucagon by Recombinant Prohormone Convertase 1 and Immunopurified Prohormone Convertase 2 in Vitro(*) , 1995, The Journal of Biological Chemistry.

[320]  W. Creutzfeldt,et al.  Binding specificity and signal transduction of receptors for glucagon-like peptide-1(7-36)amide and gastric inhibitory polypeptide on RINm5F insulinoma cells. , 1993, Journal of molecular endocrinology.

[321]  T. Suda,et al.  Relationship between molecular structures of sugars and their ability to stimulate the release of glucagon-like peptide-1 from canine ileal loops. , 1990, Acta endocrinologica.

[322]  Brown Jc,et al.  A multiparameter study on the action of preparations containing cholecystokinin-pancreozymin. , 1970 .

[323]  J. Habener,et al.  Both amidated and nonamidated forms of glucagon-like peptide I are synthesized in the rat intestine and the pancreas. , 1990, The Journal of biological chemistry.

[324]  A. Moody,et al.  Glicentin and gastric inhibitory polypeptide immunoreactivity in endocrine cells of the gut and pancreas. , 1980, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[325]  M. Namba,et al.  Glucagon-like peptide-1 (7-36 amide): a potent glucagonostatic and insulinotropic hormone. , 1988, Diabetes research and clinical practice.

[326]  M. Valdeolmillos,et al.  Glucose-dependent stimulatory effect of glucagon-like peptide 1(7-36) amide on the electrical activity of pancreatic beta-cells recorded in vivo. , 1999, Diabetes.

[327]  B. Göke,et al.  Characterization of glucagon‐like peptide‐I(7–36)amide receptors of rat lung membranes by covalent cross‐linking , 1991, FEBS letters.

[328]  D. Drucker,et al.  The caudal homeobox protein cdx-2/3 activates endogenous proglucagon gene expression in InR1-G9 islet cells. , 1997, Molecular endocrinology.

[329]  D. Drucker,et al.  The proglucagon gene upstream enhancer contains positive and negative domains important for tissue-specific proglucagon gene transcription. , 1995, Molecular endocrinology.

[330]  B. Göke,et al.  Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans. , 1998, The Journal of clinical investigation.

[331]  J. Chayvialle,et al.  Stimulation of glucagon-like peptide-1 secretion by muscarinic agonist in a murine intestinal endocrine cell line. , 1994, Endocrinology.

[332]  J. Habener,et al.  Insulinotropic Glucagon-Like Peptide I Receptor Expression in Glucagon-Producing α-Cells of the Rat Endocrine Pancreas , 1997, Diabetes.

[333]  B. Göke,et al.  Regulation of glucagon-like peptide-I receptor expression and transcription by the protein kinase C pathway , 1996, Research in experimental medicine. Zeitschrift fur die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie.

[334]  K. Kristiansen,et al.  Crystallization and amino acid sequence of duck glucagon , 1972, FEBS letters.

[335]  C. Montrose‐Rafizadeh,et al.  High Potency Antagonists of the Pancreatic Glucagon-like Peptide-1 Receptor* , 1997, The Journal of Biological Chemistry.

[336]  Andreas Wilmen,et al.  The isolated N‐terminal extracellular domain of the glucagon‐like peptide‐1 (GLP)‐1 receptor has intrinsic binding activity , 1996, FEBS letters.

[337]  E. Blázquez,et al.  Characterization of high‐affinity receptors for truncated glucagon‐like peptide‐1 in rat gastric glands , 1990, FEBS letters.

[338]  M. Namba,et al.  Decrease in blood glucose and release of gut glucagon-like immunoreactive materials by bombesin infusion in the dog. , 1980, Endocrinologia japonica.

[339]  G. Weir,et al.  Glucagon-like peptide-I-(7-37) suppresses hyperglycemia in rats. , 1993, Metabolism: clinical and experimental.

[340]  B. Göke,et al.  Characterization of GIP(1–30) and GIP(1–42) as stimulators of proinsulin gene transcription , 1995, Peptides.

[341]  Polak Jm.  The hormonal pattern of intestinal adaptation. A major role for enteroglucagon. , 1982 .

[342]  R. M. Gentry,et al.  Comparison of Fos induced in rat brain by GLP-1 and amylin , 1997, Regulatory Peptides.

[343]  M S German,et al.  Mice lacking the homeodomain transcription factor Nkx2.2 have diabetes due to arrested differentiation of pancreatic beta cells. , 1998, Development.

[344]  D. Smith,et al.  A role for glucagon-like peptide-1 in the central regulation of feeding , 1996, Nature.

[345]  S. Bloom,et al.  Molecular forms of human enteroglucagon in tissue and plasma: plasma responses to nutrient stimuli in health and in disorders of the upper gastrointestinal tract. , 1983, The Journal of clinical endocrinology and metabolism.

[346]  E. S. Edie,et al.  On the treatment of Diabetus mellitus by acid extract of Duodenal Mucous Membrane. , 1906, The Biochemical journal.

[347]  K. Nata,et al.  Nucleotide sequence determination of chicken glucagon precursor cDNA , 1990, FEBS letters.

[348]  W. Knepel,et al.  Gene-specific Transcriptional Activity of the Insulin cAMP-responsive Element Is Conferred by NF-Y in Combination with cAMP Response Element-binding Protein* , 1998, The Journal of Biological Chemistry.

[349]  P. Rorsman,et al.  Glucagon-like peptide I increases cytoplasmic calcium in insulin-secreting beta TC3-cells by enhancement of intracellular calcium mobilization. , 1995, Diabetes.

[350]  J J Misiewicz,et al.  The ileal brake--inhibition of jejunal motility after ileal fat perfusion in man. , 1984, Gut.

[351]  B. Göke,et al.  The positive charge of the imidazole side chain of histidine7 is crucial for GLP-1 action. , 1997, Endocrine journal.

[352]  A. Hamsten,et al.  The Antidiabetogenic Effect of GLP-1 Is Maintained During a 7-Day Treatment Period and Improves Diabetic Dyslipoproteinemia in NIDDM Patients , 1996, Diabetes Care.

[353]  J. Holst,et al.  The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation. , 1997, Gut.

[354]  C. Beglinger,et al.  Mechanisms of the antidiabetic action of subcutaneous glucagon-like peptide-1(7-36)amide in non-insulin dependent diabetes mellitus. , 1998, The Journal of endocrinology.

[355]  L. Orci,et al.  Glucagon-like Polypeptides in Canine Brain , 1979, Diabetes.

[356]  A. Buchan,et al.  Glucagon-like-peptide-1 secretion from canine L-cells is increased by glucose-dependent-insulinotropic peptide but unaffected by glucose. , 1998, Endocrinology.

[357]  D. Drucker,et al.  Tissue-specific differences in the levels of proglucagon-derived peptides in streptozotocin-induced diabetes. , 1989, Endocrinology.

[358]  M. Wheeler,et al.  The third cytoplasmic domain of the GLP-1[7-36 amide] receptor is required for coupling to the adenylyl cyclase system. , 1996, Endocrinology.

[359]  E. Blázquez,et al.  Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats. , 1994, The American journal of physiology.

[360]  J. Holst,et al.  Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. , 1997, The Journal of clinical endocrinology and metabolism.

[361]  T. Kato,et al.  Stimulation of truncated glucagon-like peptide-1 release from the isolated perfused canine ileum by glucose absorption. , 1994, Digestion.

[362]  F. Sundler,et al.  Gastrin-releasing peptide (GRP) in neurones of the mammalian gut , 1983, Regulatory Peptides.

[363]  B. Gallwitz,et al.  GLP-1 GIP chimeric peptides define the structural requirements for specific ligand-receptor interaction of GLP-1 , 1996, Regulatory Peptides.

[364]  J. Brown,et al.  A gastric inhibitory polypeptide. II. The complete amino acid sequence. , 1971, Canadian journal of biochemistry.

[365]  J. Holst,et al.  The Effect of Glucagon-Like Peptide I (GLP-I) on Glucose Elimination in Healthy Subjects Depends on the Pancreatic Glucoregulatory Hormones , 1996, Diabetes.

[366]  W. Knepel,et al.  Transcriptional activation of the rat glucagon gene by the cyclic AMP-responsive element in pancreatic islet cells , 1990, Molecular and cellular biology.

[367]  K. Mayo.  Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone. , 1992, Molecular endocrinology.

[368]  S. Ohashi,et al.  Comparison of the effects of various C-terminal and N-terminal fragment peptides of glucagon-like peptide-1 on insulin and glucagon release from the isolated perfused rat pancreas. , 1989, Endocrinology.

[369]  P. Rorsman,et al.  Glucagon-Like Peptide I and Glucose-Dependent Insulinotropic Polypeptide Stimulate Ca2+-Induced Secretion in Rat α-Cells by a Protein Kinase A–Mediated Mechanism , 1997, Diabetes.

[370]  P. Brubaker,et al.  Secretion of proglucagon-derived peptides in response to intestinal luminal nutrients. , 1991, Endocrinology.

[371]  G. Waeber,et al.  Glucagon-Like Peptide-I and the Control of Insulin Secretion in the Normal State and in NIDDM , 1993, Diabetes.

[372]  G. Greenberg.  Influence of vagal integrity on gastrin and somatostatin release in dogs. , 1987, Gastroenterology.

[373]  M. Rothenberg,et al.  Evidence for redundancy in propeptide/prohormone convertase activities in processing proglucagon: an antisense study. , 1996, Molecular endocrinology.

[374]  L. Thim,et al.  The primary structure of porcine glicentin (proglucagon) , 1981, Regulatory Peptides.

[375]  D. Drucker,et al.  Developmental and tissue-specific regulation of proglucagon gene expression. , 1990, Endocrinology.

[376]  R. Taylor,et al.  Ileal glucagon gene expression: ontogeny and response to massive small bowel resection. , 1990, Gastroenterology.

[377]  J. Holst,et al.  Proglucagon processing in porcine and human pancreas. , 1994, The Journal of biological chemistry.

[378]  R. Pederson,et al.  Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide. , 1999, Metabolism: clinical and experimental.

[379]  L. Morgan.  Immunoassayable Gastric Inhibitory Polypeptide: Investigations into its Role in Carbohydrate Metabolism , 1979, Annals of clinical biochemistry.

[380]  I. Valverde,et al.  Presence and characterization of glucagon-like peptide-1(7-36) amide receptors in solubilized membranes of rat adipose tissue. , 1993, Endocrinology.

[381]  R. Pederson,et al.  The Xenopus proglucagon gene encodes novel GLP-1-like peptides with insulinotropic properties. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[382]  B. Yeğen,et al.  Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. , 1997, American journal of physiology. Gastrointestinal and liver physiology.

[383]  R. Shigemoto,et al.  Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide , 1992, Neuron.

[384]  A. Macallum,et al.  The relation of the duodenal mucosa to the internal secretion of the pancreas , 1932 .

[385]  P. Brubaker,et al.  Printed in U.S.A. Copyright © 1999 by The Endocrine Society Role of the Vagus Nerve in Mediating Proximal Nutrient- Induced Glucagon-Like Peptide-1 Secretion* , 2022 .

[386]  J. Holst,et al.  Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. , 1986, Endocrinology.

[387]  W. Creutzfeldt,et al.  Influence of gastric inhibitory polypeptide antiserum on glucose-induced insulin secretion in rats. , 1982, Endocrinology.

[388]  K. Lauritsen,et al.  Gastric inhibitory polypeptide (GIP) and insulin release after small-bowel resection in man. , 1980, Scandinavian journal of gastroenterology.

[389]  I. Valverde,et al.  GLP-1 (7 - 36) Amide: Effects on Glucose Transport and Metabolism in Rat Adipose Tissue , 1997, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[390]  S. Mojsov.  Structural requirements for biological activity of glucagon-like peptide-I. , 2009, International journal of peptide and protein research.

[391]  K. Eckart,et al.  Structure/activity characterization of glucagon-like peptide-1. , 1994, European journal of biochemistry.

[392]  L. Orci,et al.  Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. , 1986, The Journal of biological chemistry.

[393]  J. Holst,et al.  GLP-1 Tablet in Type 2 Diabetes in Fasting and Postprandial Conditions , 1997, Diabetes Care.

[394]  R. Pederson,et al.  Investigation of Glucose-dependent Insulinotropic Polypeptide(1-42) and Glucagon-like Peptide-1-(7-36) Degradation in Vitro by Dipeptidyl Peptidase IV Using Matrix-assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry , 1996, The Journal of Biological Chemistry.

[395]  S. Bloom,et al.  Localization of regulatory peptides in the gut. , 1982, British medical bulletin.

[396]  John R. Christiansen,et al.  Oxyntomodulin: a potential hormone from the distal gut. Pharmacokinetics and effects on gastric acid and insulin secretion in man , 1988, European journal of clinical investigation.

[397]  Melanie G. Lee,et al.  RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor , 1998, Nature.

[398]  D. Drucker,et al.  Inhibition of pancreatic glucagon gene expression in mice bearing a subcutaneous glucagon-producing GLUTag transplantable tumor. , 1992, Molecular endocrinology.

[399]  P. J. Larsen,et al.  Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. , 1997, Endocrinology.

[400]  G. Weir,et al.  Distribution of glucagon receptors on hormone-specific endocrine cells of rat pancreatic islets. , 1996, Endocrinology.

[401]  W. Malaisse,et al.  Effects of Glucagon-Like Peptide 1 on the Kinetics of Glycogen Synthase a in Hepatocytes from Normal and Diabetic Rats. , 1998, Endocrinology.

[402]  R. Campbell,et al.  Evolution of the growth hormone-releasing factor (GRF) family of peptides. , 1992, Growth regulation.

[403]  S. Bloom,et al.  Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes. , 1998, Clinical science.

[404]  A. Crespel,et al.  Effects of glucagon and glucagon-like peptide-1 (7-36) amide (tGLP-1) on C-cells from rat thyroid and medullary thyroid carcinoma CA-77 cell line , 1996, Regulatory Peptides.

[405]  J. Egan,et al.  Regulation of glucose transporters and hexose uptake in 3T3-L1 adipocytes: glucagon-like peptide-1 and insulin interactions. , 1997, Journal of molecular endocrinology.

[406]  T. Schwartz,et al.  Glucagon and glucagon-like peptide 1: selective receptor recognition via distinct peptide epitopes. , 1994, The Journal of biological chemistry.

[407]  J. Malagelada,et al.  Participation of the jejunum and ileum in postprandial gastric secretion in man. , 1977, Gastroenterology.

[408]  G. Frost,et al.  Plasma glucagon-like peptide-1 (7-36) amide (GLP-1) response to liquid phase, solid phase, and meals of differing lipid composition. , 1998, Nutrition.

[409]  E. Blázquez,et al.  Glucagon-like peptide-1-(7-36)amide increases pulmonary surfactant secretion through a cyclic adenosine 3',5'-monophosphate-dependent protein kinase mechanism in rat type II pneumocytes. , 1998, Endocrinology.

[410]  S J de Souza,et al.  Origin of genes. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[411]  E. Pfeiffer,et al.  Release of glucagon-like immunoreactive material (GLI) from the isolated perfused jejunum of normal and diabetic rats. , 1985, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[412]  S. Seino,et al.  Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[413]  J. Holst,et al.  Subcutaneous Injection of the Incretin Hormone Glucagon-Like Peptide 1 Abolishes Postprandial Glycemia in NIDDM , 1994, Diabetes Care.

[414]  J. Raufman.  Bioactive peptides from lizard venoms , 1996, Regulatory Peptides.

[415]  D. Drucker,et al.  Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV , 1997, Nature Biotechnology.

[416]  P. Gros,et al.  Pre-proglucagon messenger ribonucleic acid: nucleotide and encoded amino acid sequences of the rat pancreatic complementary deoxyribonucleic acid. , 1984, Endocrinology.

[417]  P. Walter,et al.  Signal sequence recognition and protein targeting to the endoplasmic reticulum membrane. , 1994, Annual review of cell biology.

[418]  M. Sinha,et al.  Clinical aspects of leptin. , 1998, Vitamins and hormones.

[419]  M. McBurney,et al.  Dietary fiber modulates intestinal proglucagon messenger ribonucleic acid and postprandial secretion of glucagon-like peptide-1 and insulin in rats. , 1996, Endocrinology.

[420]  M. Nauck.  Therapeutic potential of glucagon-like peptide 1 in type 2 diabetes. , 1996, Diabetic medicine : a journal of the British Diabetic Association.

[421]  D. Barber,et al.  Morphologic and physiologic studies of canine ileal enteroglucagon-containing cells in short-term culture. , 1987, Gastroenterology.

[422]  S. Kahn,et al.  Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. , 1994, The Journal of clinical investigation.

[423]  I. Valverde,et al.  Glucagon-like peptide-1 binding to rat skeletal muscle , 1995, Peptides.

[424]  C. Luo,et al.  Evolution of glucagon genes. , 1984, Molecular biology and evolution.

[425]  S. Poulsen,et al.  Glucagonlike Peptide-I-(7–36)-Amide Receptors Only in Islets of Langerhans: Autoradiographic Survey of Extracerebral Tissues in Rats , 1991, Diabetes.

[426]  S. Kanse,et al.  Identification and characterization of glucagon‐like peptide‐1 7–36 amide‐binding sites in the rat brain and lung , 1988, FEBS letters.

[427]  J. Holst,et al.  Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. , 1999, Diabetes care.

[428]  B. Göke,et al.  Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. , 1995, Digestion.

[429]  M. Montminy,et al.  Anglerfish islet pre-proglucagon II. Nucleotide and corresponding amino acid sequence of the cDNA. , 1983, The Journal of biological chemistry.

[430]  S. Woods,et al.  Glucagon-like peptide-1 and satiety , 1997, Nature.

[431]  J. Brown,et al.  Gastric inhibitory polypeptide and glucagon-like peptide-1(7-36) amide exert similar effects on somatostatin secretion but opposite effects on gastrin secretion from the rat stomach. , 1994, Canadian journal of physiology and pharmacology.

[432]  W. E. Dixon,et al.  The Action of Intestinal Extracts , 1926, British medical journal.

[433]  J. Holst,et al.  Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)--evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins. , 1996, European journal of endocrinology.

[434]  J. Habener,et al.  Leptin receptors expressed on pancreatic beta-cells. , 1996, Biochemical and biophysical research communications.

[435]  L. Orci,et al.  PANCREATIC-POLYPEPTIDE-RICH REGIONS IN HUMAN PANCREAS , 1978, The Lancet.

[436]  D. Drucker,et al.  Intestinal growth is associated with elevated levels of glucagon-like peptide 2 in diabetic rats. , 1997, The American journal of physiology.

[437]  C. Cheeseman,et al.  The effect of GIP and glucagon-like peptides on intestinal basolateral membrane hexose transport. , 1996, The American journal of physiology.

[438]  J. Holst,et al.  Glucagonostatic Actions and Reduction of Fasting Hyperglycemia by Exogenous Glucagon-Like Peptide I(7–36) amide in type I diabetic patients , 1996, Diabetes Care.

[439]  B. Gallwitz,et al.  Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. , 1993, European journal of biochemistry.

[440]  J. Habener,et al.  Leptin inhibits insulin gene transcription and reverses hyperinsulinemia in leptin-deficient ob/ob mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[441]  I. Valverde,et al.  Lipolytic action of glucagon-like peptides in isolated rat adipocytes , 1992, Peptides.

[442]  J. Holst,et al.  Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2). , 1987, Scandinavian journal of clinical and laboratory investigation.

[443]  V. Marks,et al.  GIP and GLP-1(7-36)amide secretion in response to intraduodenal infusions of nutrients in pigs. , 1995, Comparative biochemistry and physiology. Part C, Pharmacology, toxicology & endocrinology.

[444]  D. Steiner,et al.  Mutations in the guinea pig preproglucagon gene are restricted to a specific portion of the prohormone sequence , 1986, FEBS letters.

[445]  G. Géraud,et al.  Dipeptidyl peptidase IV expression in rat jejunal crypt-villus axis is controlled at mRNA level. , 1991, The American journal of physiology.

[446]  R. Bruzzone,et al.  Effect of bombesin on plasma insulin, pancreatic glucagon, and gut glucagon in man. , 1983, The Journal of clinical endocrinology and metabolism.

[447]  D J Drucker,et al.  Printed in U.S.A. Copyright © 1998 by The Endocrine Society Regulation of Glucagon-Like Peptide-1 Synthesis and , 2022 .

[448]  G. Bell,et al.  Hamster preproglucagon contains the sequence of glucagon and two related peptides , 1983, Nature.

[449]  M. Igarashi,et al.  Hypersecretion of Truncated Glucagon‐like Peptide‐1 and Gastric Inhibitory Polypeptide in Obese Patients , 1993 .

[450]  L. Orci,et al.  Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[451]  J. Levy,et al.  Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM , 1997, Diabetologia.

[452]  J. Holst,et al.  Effect of truncated glucagon‐like peptide 1 on cAMP in rat gastric glands and HGT‐1 human gastric cancer cells , 1988, FEBS letters.

[453]  H. Vermeer,et al.  Glucagon‐like peptide‐1 cells in the gastrointestinal tract and pancreas of rat, pig and man , 1992, European journal of clinical investigation.

[454]  S. Bloom,et al.  Glucagon-like peptide-1 (7-36)-NH2: a physiological inhibitor of gastric acid secretion in man. , 1990, The Journal of endocrinology.

[455]  B. Göke,et al.  Endoproteolysis of Glucagon-like Peptide (GLP)-1(7–36) amide by Ectopeptidases in RINm5F Cells , 1997, Peptides.

[456]  W. Rutter,et al.  Onset of cell-specific gene expression in the developing mouse pancreas. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[457]  S. Woods,et al.  University of Groningen Central infusion of GLP-1, but not leptin, produces conditioned taste aversions in rats , 2002 .

[458]  N. Mcintyre,et al.  NEW INTERPRETATION OF ORAL GLUCOSE TOLERANCE. , 1964, Lancet.

[459]  W M Bayliss,et al.  The mechanism of pancreatic secretion , 1902, The Journal of physiology.

[460]  J. Habener,et al.  Point mutations in the first and third intracellular loops of the glucagon-like peptide-1 receptor alter intracellular signaling. , 1996, Biochemical and biophysical research communications.

[461]  B. Ahrén,et al.  Effects of glucagon like-1(7–36)amide on the ctoplasmic Ca2+-concentration in rat islet cells , 1993, Molecular and Cellular Endocrinology.

[462]  D. Bataille,et al.  Comparative effects of GLP-1-(7-36) amide, oxyntomodulin and glucagon on rabbit gastric parietal cell function. , 1995, European journal of pharmacology.

[463]  L. Thim,et al.  Somatostatin-related and glucagon-related peptides with unusual structural features from the European eel (Anguilla anguilla). , 1988, General and comparative endocrinology.

[464]  I. Valverde,et al.  Glucagon-like peptide-1 binding to rat hepatic membranes. , 1995, The Journal of endocrinology.

[465]  A. Astrup,et al.  Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. , 1998, The Journal of clinical investigation.

[466]  J. Habener,et al.  Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. , 1996, Endocrinology.

[467]  P. F. Nielsen,et al.  Isolation and Structural Characterization of Proglucagon-Derived Peptides, Pancreatic Polypeptide, and Somatostatin from the UrodeleAmphiuma tridactylum , 1996 .

[468]  M. Nauck,et al.  Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. , 1993, The Journal of clinical endocrinology and metabolism.

[469]  J. Holst,et al.  Complete sequences of glucagon-like peptide-1 from human and pig small intestine. , 1989, The Journal of biological chemistry.

[470]  D. Drucker,et al.  Tissue-specific Expression of Unique mRNAs That Encode Proglucagon-derived Peptides or Exendin 4 in the Lizard* , 1997, The Journal of Biological Chemistry.

[471]  M. Loeffler,et al.  Stem cells: attributes, cycles, spirals, pitfalls and uncertainties. Lessons for and from the crypt. , 1990, Development.

[472]  B. Göke,et al.  Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7–36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides , 1995, Regulatory Peptides.

[473]  P. J. Larsen,et al.  Glucagon-like peptide 1(7-36) amide's central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment. , 1998, Diabetes.

[474]  J. Rouse,et al.  Isolation of alligator gar (Lepisosteus spatula) glucagon, oxyntomodulin, and glucagon-like peptide: amino acid sequences of oxyntomodulin and glucagon-like peptide. , 1988, General and comparative endocrinology.

[475]  M. Ohneda,et al.  Response of gut glucagon-like immunoreactivity to hypoglycemia in dogs. , 1989, The American journal of physiology.

[476]  I. Valverde,et al.  Renal catabolism of truncated glucagon-like peptide 1. , 1993, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[477]  Y. Kaziro,et al.  Molecular cloning and expression of a cDNA encoding the secretin receptor. , 1991, The EMBO journal.

[478]  B. Göke,et al.  Differential effects of subcutaneous GLP-1 on gastric emptying, antroduodenal motility, and pancreatic function in men. , 1997, Proceedings of the Association of American Physicians.

[479]  J. Polak,et al.  Endocrine tumour in kidney affecting small bowel structure, motility, and absorptive function 1 , 1971, Gut.

[480]  B. Thorens,et al.  Agonist-induced internalization and recycling of the glucagon-like peptide-1 receptor in transfected fibroblasts and in insulinomas. , 1995, The Biochemical journal.

[481]  G. Fink,et al.  The VIP2 receptor: Molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide , 1993, FEBS letters.

[482]  Laurent Journot,et al.  Differential signal transduction by five splice variants of the PACAP receptor , 1993, Nature.

[483]  L. Orci,et al.  Embryogenesis of the murine endocrine pancreas; early expression of pancreatic polypeptide gene. , 1991, Development.

[484]  J. Holst,et al.  Rapid oscillations in plasma glucagon-like peptide-1 (GLP-1) in humans: cholinergic control of GLP-1 secretion via muscarinic receptors. , 1997, The Journal of clinical endocrinology and metabolism.

[485]  G. Weir,et al.  Glucagon-like peptide-I analogs: effects on insulin secretion and adenosine 3',5'-monophosphate formation. , 1990, Endocrinology.

[486]  D. Drucker,et al.  Alpha-cell-specific expression of the glucagon gene is conferred to the glucagon promoter element by the interactions of DNA-binding proteins , 1988, Molecular and cellular biology.

[487]  D. Drucker,et al.  Glucagon and related peptides in fetal rat hypothalamus in vivo and in vitro. , 1990, Endocrinology.

[488]  D. Litthauer,et al.  Purification and primary structure of glucagon from ostrich pancreas splenic lobes. , 2009, International journal of peptide and protein research.

[489]  D. Smith,et al.  Glucagon-like peptide-1 stimulates luteinizing hormone-releasing hormone secretion in a rodent hypothalamic neuronal cell line. , 1998, The Journal of clinical investigation.

[490]  A. Edvell,et al.  Initiation of Increased Pancreatic Islet Growth in Young Normoglycemic Mice (Umeå +/?). , 1999, Endocrinology.

[491]  G. Singhg,et al.  Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. Identification of a mammalian analogue of the reptilian peptide exendin-4. , 1992, The Journal of biological chemistry.

[492]  D. Barber,et al.  Fatty acids stereospecifically stimulate neurotensin release and increase [Ca2+]i in enteric endocrine cells. , 1991, The American journal of physiology.

[493]  L. Orci,et al.  Glicentin immunoreactive cells: their relationship to glucagon-producing cells. , 1979, Endocrinology.

[494]  M. Classen,et al.  Comparison of GLP-1 (7-36amide) and GIP on release of somatostatin-like immunoreactivity and insulin from the isolated rat pancreas. , 1990, Zeitschrift fur Gastroenterologie.

[495]  S. Bloom,et al.  Glucagon‐like peptide‐1 (GLP‐1): a trial of treatment in non‐insulin‐dependent diabetes mellitus , 1997, European journal of clinical investigation.

[496]  P. MacDonald,et al.  Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs. , 1999, Diabetes.

[497]  D. Irwin,et al.  Trout and chicken proglucagon: alternative splicing generates mRNA transcripts encoding glucagon-like peptide 2. , 1995, Molecular endocrinology.

[498]  R. Yalow,et al.  Rhesus monkey gastroenteropancreatic hormones: relationship to human sequences , 1991, Regulatory Peptides.

[499]  J. Epelbaum,et al.  Molecular pharmacology of somatostatin receptors , 1995, Fundamental & clinical pharmacology.

[500]  L. Uttenthal,et al.  Identification of amidated forms of GLP-1 in rat tissues using a highly sensitive radioimmunoassay , 1997, Regulatory Peptides.

[501]  P. Andrews,et al.  Isolation and structures of glucagon and glucagon-like peptide from catfish pancreas. , 1985, The Journal of biological chemistry.

[502]  A. Terzic,et al.  The sulfonylurea controversy: more questions from the heart. , 1998, Journal of the American College of Cardiology.

[503]  J. Holst,et al.  Carboxypeptidase‐B‐like processing of the C‐terminus of glucagon‐like peptide‐2 in pig and human small intestine , 1989, FEBS letters.

[504]  B. Göke,et al.  Exchange of W39 by A within the N-terminal extracellular domain of the GLP-1 receptor results in a loss of receptor function , 1996, Peptides.

[505]  J. Philippe,et al.  Islet-specific Proteins Interact with the Insulin-response Element of the Glucagon Gene (*) , 1995, The Journal of Biological Chemistry.

[506]  P. J. Larsen,et al.  Identification of specific binding sites for glucagon-like peptide-1 on the posterior lobe of the rat pituitary. , 1995, Neuroendocrinology.

[507]  R. Matesanz,et al.  Chromatographic pattern of gut glucagon-like immunoreactivity (GLI) in plasma before and during glucose absorption. , 1979, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[508]  A. Ryan,et al.  Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia. , 1998, The Journal of clinical endocrinology and metabolism.

[509]  R. Pederson,et al.  Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice. , 1998, Diabetes.

[510]  G. Weir,et al.  Glucagonlike Peptide I (7–37) Actions on Endocrine Pancreas , 1989, Diabetes.

[511]  J. Holst,et al.  Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. , 1996, The American journal of physiology.

[512]  J. Furness,et al.  Neuronal peptides in the intestine. , 1982, British medical bulletin.

[513]  B. Göke,et al.  Glucagon-like peptide-1(7–37)/(7–36)amide is a new incretin , 1992, Molecular and Cellular Endocrinology.

[514]  B. Göke,et al.  Characterization of receptors for glucagon‐like peptide‐1(7–36) amide on rat lung membranes , 1990, FEBS letters.

[515]  G. Ramadori,et al.  Release of glucagon-like peptide-1 (GLP-1) by carbohydrates in the perfused rat ileum , 1997, Acta Diabetologica.

[516]  G. Bell.  The glucagon superfamily: Precursor structure and gene organization , 1986, Peptides.

[517]  M. Sunagawa,et al.  ATP-sensitive K+ channels in pancreatic, cardiac, and vascular smooth muscle cells. , 1998, American journal of physiology. Cell physiology.

[518]  N. Wright,et al.  Influence of somatostatin and bombesin on plasma enteroglucagon and cell proliferation after intestinal resection in the rat. , 1985, Gut.

[519]  J. Holst,et al.  Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. , 1998, Diabetes.

[520]  W. Malaisse,et al.  Exendin-4 agonist and exendin(9-39)amide antagonist of the GLP-1(7-36)amide effects in liver and muscle. , 1997, Archives of biochemistry and biophysics.

[521]  J. Brown,et al.  Gastric inhibitory polypeptide release from a tumor-derived cell line. , 1995, The American journal of physiology.

[522]  S. Wank,et al.  Molecular Cloning of the Helodermin and Exendin-4 cDNAs in the Lizard , 1998, The Journal of Biological Chemistry.

[523]  J. Livingston,et al.  Glucagon·Glucagon-like Peptide I Receptor Chimeras Reveal Domains That Determine Specificity of Glucagon Binding (*) , 1995, The Journal of Biological Chemistry.

[524]  R. K. Lim,et al.  Demonstration of the Humoral Agent in Fat Inhibition of Gastric Secretion. , 1930 .

[525]  J. Brown.  A gastric inhibitory polypeptide. I. The amino acid composition and the tryptic peptides. , 1971, Canadian journal of biochemistry.

[526]  T. M. Nguyen,et al.  Characterization of insulins and proglucagon-derived peptides from a phylogenetically ancient fish, the paddlefish (Polyodon spathula). , 1994, The Biochemical journal.

[527]  V. Marks,et al.  Attenuated GLP-1 secretion in obesity: cause or consequence? , 1996, Gut.

[528]  R. Murphy,et al.  The use of perfused rat intestine to characterise the glucagon-like immunoreactivity released into serosal secretions following stimulation by glucose. , 1979, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[529]  J. Chayvialle,et al.  Regulation of glucagon-like peptide-1-(7-36) amide, peptide YY, and neurotensin secretion by neurotransmitters and gut hormones in the isolated vascularly perfused rat ileum. , 1995, Endocrinology.

[530]  M. Schwaninger,et al.  Characterization of a novel protein kinase C response element in the glucagon gene , 1997, Molecular and cellular biology.

[531]  J. Holst,et al.  Naturally occurring products of proglucagon 111-160 in the porcine and human small intestine. , 1988, The Journal of biological chemistry.

[532]  E. Blázquez,et al.  Interactions of exendin-(9–39) with the effects of glucagon-like peptide-1-(7–36) amide and of exendin-4 on arterial blood pressure and heart rate in rats , 1996, Regulatory Peptides.

[533]  K. Minaker,et al.  The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7–37) in normal and diabetic subjects , 1994, Regulatory Peptides.

[534]  J. Holst,et al.  Glucagonlike peptide 1: a newly discovered gastrointestinal hormone. , 1994, Gastroenterology.

[535]  R. Unger,et al.  Characterization of response of circulating glucagon to intraduodenal and intravenous administration of amino acids. , 1968, The Journal of clinical investigation.

[536]  B. Göke,et al.  Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. , 1995, Endocrine reviews.

[537]  D. Drucker,et al.  Multiple cis-acting domains mediate basal and adenosine 3',5'-monophosphate-dependent glucagon gene transcription in a mouse neuroendocrine cell line. , 1993, Endocrinology.

[538]  B. Göke,et al.  Reduction of the Incretin Effect in Rats by the Glucagon-Like Peptide 1 Receptor Antagonist Exendin (9–39) Amide , 1995, Diabetes.

[539]  J. Holst,et al.  The Inhibitory Effect of Glucagon-Like Peptide-1 (7-36)amide on Antral Motility is Antagonized by Its N-Terminally Truncated Primary Metabolite GLP-1 (9-36)amide , 1998, Peptides.